Anavex Life Sciences Corp (AVXL)

[RedShoulder]

"Eli Lilly adds $23B in market cap as investors rush on promise that this will be the amyloid Alzheimer's drug that works
On a scale that measures cognition, patients who received Lilly's donanemab had a 35% slower decline vs. the placebo recipients. On a measurement of activities of daily living, donanemab patients showed a 40% slower decline compared with the placebo group."
https://endpts.com/eli-lilly-adds-23b-in-market-cap-as-investors-rush-on-promise-that-this-will-be-the-amyloid-alzheimers-drug-that-works/

"But there are caveats in the data. Those numbers pertain only to patients with intermediate levels of a protein called tau in the brain. Tau is associated with Alzheimer's disease. Across all patients, including those with high levels of tau, donanemab led to a 22% slower decline in cognition on the same scale."

In Lilly's study, temporary swelling occurred in 24% of donanemab recipients, and 6.1% of those reported symptoms. Brain bleeding, another form of ARIA, occurred in 31.4% of donanemab patients. In Biogen's study, 12.6% of patients had brain swelling, including 2.8% with symptoms. Another 17.3% of patients experienced brain bleeding, William Blair analyst Myles Minter said in a note.

Notably, three patients died due to or after experiencing serious ARIA in Lilly's study. In Biogen's Phase 2 study, none of the patients died due to ARIA. In a final-phase study, two Leqembi recipients died, but the deaths weren't deemed to be ARIA-related, Evercore ISI analyst Umer Raffat said in a note.
https://www.investors.com/news/technology/eli-lilly-stock-surges-after-alzheimers-treatment-succeeds-in-final-phase-study/?src=A00220
---------------------------------------------------------------

Lily's drug slows the decline by 36% slower cognitive decline as measured by CDR-SB. But when accounting for all patients, including those with high tau levels, the experimental Alzheimer's treatment led to a 29% slower decline in cognition vs. the placebo. That says the decline continues, just at a slower rate.

The biggest concern is that temporary swelling occurred in 24% of donanemab recipients and 17.3% of patients experienced brain bleeding.

Anavex safety profile makes it a winner over Biogen's and Lilly's infusion drugs. All Anavex has to do is show better efficacy than Biogen's and Lilly's drugs; which with Anavex's AD trial meeting all primary and secondary end points that should show much better efficacy than Lilly's and Biogen's efficacy. With that, Anavex will have a clear win with the most important safety factor in play, lower cost, no periodic brain scans to check for brain swelling and brain bleeds, and no office visits for the IV drugs.

Anavex is not killing patients with serious adverse effects, nor brain swelling and brain bleeds in any of it's trials with A2-73 Blarcamesine..

What would an increase of $23 Billion in Market Cap do for Anavex's share price?